Search projects
20 projects found
ENABLE
f7608d62-5f11-11eb-917b-acde48001122
European Gram-negative Antibacterial Engine
Keywords: IMI projects Antimicrobial resistance Infectious diseases ND4BB Drug discovery
ERA4TB
f17922f6-5f11-11eb-917b-acde48001122
European regimen accelerator for tuberculosis
Keywords: IMI projects Antimicrobial resistance Infectious diseases AMR Accelerator
GNA NOW
f48896de-5f11-11eb-917b-acde48001122
Novel Gram-negative antibiotic now
Keywords: IMI projects Antimicrobial resistance Infectious diseases AMR Accelerator Conducting clinical trials

ND4BB
dc9bffc0-147a-11eb-b51f-8c8590c45a21
New Drugs for Bad Bugs. Umbrella programme comprising the IMI projects TRANSLOCATION, ENABLE, COMBACTE-NET, COMBACTE-CARE, COMBACTE-MAGNET, COMBACTE-CDI, iABC and DRIVE-AB
Keywords: IMI projects Antimicrobial resistance Infectious diseases ND4BB Clinical trial design Conducting clinical trials Clinical networks Real-world data, evidence Drug discovery Economic model
PRIMAVERA
c905e85a-c98a-11ed-a11d-ea435b63c148
Predicting the impact of monoclonal antibodies & vaccines on antimicrobial resistance
Keywords: IMI projects Antimicrobial resistance Infectious diseases Vaccines Biologicals AMR Accelerator Economic model
RespiriNTM
f4e40262-5f11-11eb-917b-acde48001122
Progress novel assets (one FIH start) for non-tubercular mycobacteria that may act synergistically with bedaquiline and cytochrome bc drugs
Keywords: IMI projects Antimicrobial resistance Infectious diseases AMR Accelerator Conducting clinical trials Target identification
RespiriTB
f32fb9f2-5f11-11eb-917b-acde48001122
Progress new assets (one pre-new molecular entity and one first-time-in-human start) for tuberculosis that act synergistically with bedaquiline, cytochrome bc or cytochrome bd inhibitors
Keywords: IMI projects Antimicrobial resistance Infectious diseases AMR Accelerator Conducting clinical trials
TRANSLOCATION
f0233b12-5f11-11eb-917b-acde48001122
Molecular basis of the bacterial cell wall permeability
Keywords: IMI projects Antimicrobial resistance Infectious diseases ND4BB Drug discovery
